SOURCE: Targeted Molecular Diagnostics (TMD)

March 19, 2008 09:00 ET

Targeted Molecular Diagnostics Launches PhosphoGuard™ -- a Preservative for Phosphorylated Proteins

WESTMONT, IL--(Marketwire - March 19, 2008) - Targeted Molecular Diagnostics, LLC (TMD) announces the availability of the PhosphoGuard™ kit for preservation of phosphoproteins during tissue fixation and processing.

When used as an additive to conventional fixatives, PhosphoGuard™ can prevent degradation of phosphorylated or "activated" proteins in patient tissue or xenograft specimens. Phosphorylated proteins are useful markers that may be essential in predicting patient response or resistance to targeted cancer therapies. Endogenous phosphatases are ubiquitously present and often impede the detection of these phosphorylated antigens by immunohistochemistry (IHC). TMD has formulated a proprietary solution of broad-spectrum phosphatase inhibitors in the PhosphoGuard™ kit which has been used in several Phase II and III oncology clinical trials for targeted therapies such as Tykerb.

"The development of PhosphoGuard™ represents a significant evolution in the preanalytical management of vital cancer specimens which will contribute to more reliable and standardized assessment by IHC. We expect PhosphoGuard™ to improve the quality of data and subsequently, contribute to improved clinical trial design and patient care," states Mr. Christopher Ung of TMD who commercialized the first widely used pharmacodiagnostic test kit for selecting women with breast cancer who may benefit from Herceptin treatment.

PhosphoGuard™ is available in a 10-test research use format or as a comprehensive single use kit designed for use in clinical trials. For more information about PhosphoGuard™, please contact TMD at or toll free 866-897-7350.

Targeted Molecular Diagnostics, LLC ( is focused on the development and performance of targeted cancer diagnostic tests to enable personalized cancer treatment. TMD has pioneered the use of biomarkers to advance clinical trials for biopharmaceutical companies and is involved in numerous ongoing studies and clinical programs. The company was founded in 2004, is privately held, and has clinical and research laboratories located in the Chicago suburb of Westmont, IL. For more information call 866-897-7350 or visit

Contact Information

  • Targeted Molecular Diagnostics
    610 Oakmont Lane
    Westmont, Il 60559

    Andrea Jones